不同放化疗方案在局限期小细胞肺癌患者中的应用效果  

Application effect of different chemoradiotherapy regimens in patients with limited-stage small cell lung cancer

作　　者：张一鸣 曹芬芬 刘亚茹 ZHANG Yiming;CAO Fenfen;LIU Yaru(Department of Internal Medicine,Jingdezhen Hospital of Traditional Chinese Medicine,Jingdezhen 333000,Jiangxi,China;Department of Pharmacy,Jingdezhen Hospital of Traditional Chinese Medicine,Jingdezhen 333000,Jiangxi,China)

机构地区：[1]景德镇市中医医院内科,江西景德镇3330000 [2]景德镇市中医医院药剂科,江西景德镇3330000

出　　处：《癌症进展》2024年第23期2596-2599,共4页Oncology Progress

基　　金：江西省中医药管理局科技计划项目(2023A0284)。

摘　　要：目的 探讨不同放化疗方案在局限期小细胞肺癌(SCLC)患者中的应用效果。方法 选取52例行依托泊苷+顺铂(EP)方案化疗联合胸部立体定向放射治疗的局限期SCLC患者,根据放化疗方案的不同分为同步放化疗组(31例)和序贯放化疗组(21例),同步放化疗组患者同步进行放化疗,序贯放化疗组患者化疗结束后间隔2天进行放疗。比较两组患者的临床疗效、肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)]、不良反应发生情况及生存情况。结果 两组患者的总有效率和不良反应总发生率比较,差异均无统计学意义(P>0.05)。治疗后,两组患者CA125、CEA水平均低于本组治疗前,同步放化疗组患者CA125、CEA水平均低于序贯放化疗组,差异均有统计学意义(P<0.05)。同步放化疗组患者的中位生存时间为8个月,明显长于序贯放化疗组的7个月,差异有统计学意义(P<0.01)。结论 同步放化疗与序贯放化疗治疗局限期SCLC患者的疗效和安全性相当,但同步放化疗可迅速降低肿瘤标志物水平,有效控制肿瘤转移,并且延长患者的中位生存时间。Objective To investigate the application effect of different chemoradiotherapy regimens in patients with limited-stage small cell lung cancer(SCLC).Method A total of 52 patients with limited-stage SCLC who underwent eto-poside+cisplatin(EP)regimen chemotherapy combined with thoracic stereotactic radiotherapy were selected and divided into synchronous chemoradiotherapy group(31 cases)and sequential chemoradiotherapy group(21 cases)according to different chemoradiotherapy regimens.Patients in the synchronous chemoradiotherapy group received radiotherapy and chemotherapy simultaneously.Patients in the sequential chemoradiotherapy group received radiotherapy with two days in-terval after chemotherapy.The clinical efficacy,tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic an-tigen(CEA)],incidence of adverse reactions and survival were compared between the two groups.Result There were no significant differences in the total effective rate and total incidence of adverse reactions between the two groups(P>0.05).After treatment,the levels of CA125 and CEA in two groups were lower than those before treatment,the levels of CA125 and CEA in synchronous chemoradiotherapy group were lower than those in sequential chemoradiotherapy group,and the differences were statistically significant(P<0.05).The median survival time of patients in the synchronous chemo-radiotherapy group was 8 months,which was significantly longer than 7 months in the sequential chemoradiotherapy group,and the difference was statistically significant(P<0.01).Conclusion Synchronous chemoradiotherapy and se-quential chemoradiotherapy have the same efficacy and safety in the treatment of patients with limited-stage SCLC.How-ever,synchronous chemoradiotherapy can rapidly reduce the levels of tumor markers,effectively control tumor metasta-sis,and prolong the median survival time.

关 键 词：小细胞肺癌 序贯放化疗 同步放化疗 

分 类 号：R734.2[医药卫生—肿瘤]